This is the authors' abstract. We don't add key points for this paper.
The results of our study highlight that treatment with secukinumab in patients with severe HS who failed adalimumab may be a safe and effective therapeutic weapon.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Martora et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: